|Bid||0.5851 x 1100|
|Ask||0.6179 x 1800|
|Day's Range||0.5626 - 0.6386|
|52 Week Range||0.5600 - 4.7300|
|Beta (5Y Monthly)||1.09|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 22, 2022 - Mar 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.33|
EVANSTON, Ill., May 18, 2022--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that company management will present at the H.C. Wainwright Global Investment Conference to be held May 23-26, 2022. The presentation will be available on-demand through the H.C. Wainwright conference portal, beginning at 7:00 AM ET on Tuesday, May 24, 2022.
EVANSTON, Ill., May 17, 2022--Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that data from preclinical studies of NYX-783 in models of post-traumatic stress disorder (PTSD) will be presented in a poster at the American Psychiatric Association Annual Meeting being held May 21 – 25, 2022 in New Orleans, LA.
On today's call, Andy Kidd, our president and chief executive officer, will discuss our business and clinical development progress; then Ashish Khanna, our chief financial officer and chief business officer, will review our financial results. Please see the forward-looking statement disclaimer in our financial results release issued this afternoon and the risk factors in the company's current and subsequent filings with the SEC.